Quintessence Publishing: Events

Share Page:

Thursday, June 6
Friday, June 7
Saturday, June 8
Sunday, June 9

Session III: Treatment-Planning Innovations for the Compromised Patient

Prognoses, Risk Factors, and Solutions for Periodontally Compromised Patients

Myron Nevins
Saturday, June 8
9:15 am - 10:15 am
Grand Ballroom (Salon G-K)

Every patient relies on our cognitive skills to alert them to the risks inherent in any proposed treatment plan. This presentation will assume that the patient is healthy and can afford any necessary therapies. The overriding question: What would we do if the roles were reversed and we were the patient? How do we establish realistic prognoses for periodontally compromised teeth? Which teeth will respond to regenerative therapies, and when is the prognosis improved with implants? These questions are especially significant when the compromise is located in the esthetic zone and there is vertical bone loss that challenges the requirement for optimal results. Can we ignore the biologic width and place restorative materials subgingivally in this category of patients? Furcation invasions are another factor. We need to establish criteria for success as a means of realizing the prognosis. The combination of these issues and concerns will determine the realistic prognosis of the treatment plan when interdisciplinary care is involved.

Myron Nevins, DDS, is the editor of the International Journal of Periodontics and Restorative Dentistry. He is an associate clinical professor of periodontology at the Harvard School of Dental Medicine and a professor of periodontics at the University of Pennsylvania School of Dentistry. Dr Nevins is a past president of the American Academy of Periodontology and a former director and chairman of the American Board of Periodontology, where his contributions have been recognized with the Gold Medal and the Master Clinician Awards. He maintains a private practice limited to periodontics and implantology in Swampscott, Massachusetts, and is the founder and president of Perio Imp Research, Inc.